Olaparib in Locally Advanced ER, PgR and HER2 Negative (Triple Negative) and in Locally Advanced Germline BRCA Mutation-positive Breast Cancer Patients

NCT02681562 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

45

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer
Triple Negative Breast Cancer

Interventions

DRUG: olaparib

Sponsor

Istituti Ospitalieri di Cremona